September 08, 2025 a 05:01 pm
DXCM: Analysts Ratings - DexCom, Inc.
DexCom, Inc. continues to showcase its stable position in the market with a strong buy and buy ratings forming the majority of analyst recommendations. With no sell ratings, the company demonstrates resilience and maintains investor confidence. Notably, shifts between strong buy and buy indicate possible sentiment adjustments among analysts.
Historical Stock Grades
Recent analyst ratings for DexCom, Inc. (DXCM) reveal a predominantly positive outlook, with 3 strong buys, 20 buys, and 4 holds as of September 2025. The absence of sell or strong sell ratings indicates continued market confidence.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 20 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, there has been a noticeable shift in analyst sentiment concerning DexCom, Inc.:
- The total number of analyst ratings has remained largely consistent, with a slight decrease in strong buy ratings from 6 to 3 within the last months.
- A subtle increase in buy ratings shows continued confidence, while hold ratings have marginally fluctuated.
- No movement has been seen in sell categories, marking steady overall market sentiment towards DXCM.
Percentage Trends
Examining the percentage trends of analyst ratings reveals key observations:
- The proportion of strong buy ratings decreased from 20% to 15% within the last few months.
- Buy ratings maintain a dominant presence, inching upwards by 10% recently.
- The stability of hold ratings indicates a consistent assessment amid changing market conditions.
- Overall, there has been a gradual shift towards a more conservative outlook from extremely bullish sentiments observed earlier.
Latest Analyst Recommendations
Recent recommendations for DXCM mostly consist of maintained ratings, reflecting ongoing confidence in the company:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| August 2025 | Buy | Buy | Canaccord Genuity |
| July 2025 | Overweight | Overweight | Piper Sandler |
| July 2025 | Outperform | Outperform | Oppenheimer |
| July 2025 | Buy | Buy | UBS |
| July 2025 | Strong Buy | Strong Buy | Raymond James |
Analyst Recommendations with Change of Opinion
Analyzing changes in analyst opinions offers insights regarding recent upgrades and downgrades:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| February 2025 | Buy | Neutral | Redburn Atlantic |
| January 2025 | Outperform | Neutral | Baird |
| July 2024 | Neutral | Outperform | Baird |
| July 2024 | Neutral | Overweight | JP Morgan |
| April 2023 | Strong Buy | Outperform | Raymond James |
Interpretation
The overall positive sentiment from analysts regarding DXCM is indicative of strong market confidence. The absence of sell recommendations underscores the company's strength in navigating market challenges. However, the recent shift from strong buy to buy may suggest cautious optimism among analysts, possibly responding to market conditions or internal performance metrics. Stability in recommendations reflects consistent performance and strategic alignment, while shifts in strong buy ratings may indicate careful scrutiny by analysts seeking to balance expectations.
Conclusion
In summary, DexCom, Inc. remains a resilient entity within its industry, sustaining strong buy and buy recommendations. While shifts in strong buy ratings suggest measured optimism, they also highlight potential for growth. The steadfast absence of sell ratings denotes sustained investor confidence, positioning DXCM favorably amidst its competitors. As the landscape evolves, continued monitoring of upgrades and downgrades will provide clearer insights into future performance potentials and underlying market conditions.